|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VASCULAR BIOLOGY
Department of Pathology, Saint Louis University School of Medicine, St. Louis, Missouri
Submitted 10 July 2007 ; accepted in final form 22 August 2007
| ABSTRACT |
|---|
|
|
|---|
endothelium; arrhythmogenesis; inflammation; lysophospholipids
There are limited studies in the literature concerning the cardiovascular effects of lysoPlsCho. Interestingly, lysoPlsCho alters the electrophysiological properties of normoxic myocytes at significantly lower concentrations than those previously described for structurally similar compounds, suggesting that there may be a direct interaction between this metabolite and several integral membrane proteins (10). LysoPlsCho also activates myocardial cAMP-dependent protein kinase (19), suggesting a role in signal transduction analogous to that of diacylglycerol activation of protein kinase C.
Although lysoPlsCho has been implicated in arrhythmogenesis following the onset of myocardial ischemia, to date there have been no studies demonstrating the effect of this compound on the coronary vasculature after release from the endothelium. We have demonstrated (18) that thrombin- and tryptase-stimulated HCAEC increase platelet-activating factor (PAF) production and cell surface expression of P-selectin, both processes that can contribute to increased neutrophil adherence and transmigration, illustrating a role for these proteases in inflammation. In this study, we explore the hypothesis that our previously observed effects may be mediated, at least in part, by lysoPlsCho, implicating this metabolite as an inflammatory mediator in the coronary vasculature and a modulator of the progression of atherosclerosis, in addition to its previously described role in arrhythmogenesis.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture of HCAEC. HCAEC were obtained from Lonza (Walkersville, MD). Endothelial cells were grown in MCDB-131 medium with 5% fetal bovine serum (FBS), 10 ng/ml epidermal growth factor, 1 µg/mg hydrocortisone, 200 µg/ml endothelial cell growth supplement, and 90 µg/ml heparin. Cells were allowed to grow to confluence, achieving a contact-inhibited monolayer of flattened, closely apposed endothelial cells in 4–5 days. After achieving confluence, cells were passaged in a 1:3 dilution and cells from passages 3–4 used for experiments.
HCAEC stimulation. LysoPlsCho, lysoPtdCho, or thrombin was diluted with medium (for assay of neutrophil adhesion) or Hanks' balanced salt solution (for assay of adhesion molecule surface expression). Stimulant was added to the cell culture plate, and the plate was gently rotated to ensure thorough mixing and even distribution of stimulant across the HCAEC monolayer.
Choline lysophospholipid production. LysoPlsCho and lysoPtdCho were measured with a modification of a radiometric assay method developed previously (11). Lipids were extracted from HCAEC and the surrounding medium by the method of Bligh and Dyer (4), and lysophospholipids were separated from other phospholipids by HPLC. The purified lysoPlsCho and lysoPtdCho fractions were acetylated with [3H]acetic anhydride, using 0.33 M dimethylaminopyridine as a catalyst. The acetylated lysophospholipid was then separated by thin-layer chromatography, and radioactivity was quantified by liquid scintillation spectrometry. Standard curves were constructed, and lysoPlsCho and lysoPtdCho content were derived for all samples and normalized according to the protein content of HCAEC. [14C]lysoPtdCho was added as an internal standard to all samples to correct for the loss of sample that occurred during extraction, purification, and acetylation.
Cell surface expression of adhesion molecules. HCAEC, grown to confluence in 16-mm culture dishes, were incubated with stimulant in Hanks' buffer for 5 min at 37°C in 95% O2-5% CO2. At the end of the incubations buffer was quickly removed, and cells were immediately fixed with 1% paraformaldehyde and incubated overnight at 4°C. Cells were then washed three times with phosphate-buffered saline (PBS) and then blocked with Tris-buffered saline-Tween supplemented with 0.8% BSA (wt/vol) and 0.5% fish gelatin (wt/vol) for 1 h at 24°C. Appropriate primary antibody (1:50) was used before treatment with horseradish peroxidase-conjugated rabbit anti-goat secondary antibody (1:5,000). Subsequently, each well was incubated in the dark with the 3,3',5,5'-tetramethylbenzidine liquid substrate system. Reactions were stopped by the addition of sulfuric acid, and color development was measured with a microtiter plate spectrophotometer at 450 nm.
Isolation of neutrophils from human peripheral blood. Adult peripheral blood was collected from volunteers in vials containing 3.8% sodium citrate to inhibit coagulation. The protocol was approved by the Institutional Review Board of Saint Louis University School of Medicine, and all volunteers gave informed consent. Equal volumes of whole blood were layered over Polymorphprep (Axis-Shield PoC, Oslo, Norway) in a 50-ml conical tube. Tubes were spun at 500 g for 30 min at 20°C with no brake. The top band at the sample/medium interface consisting of mononuclear cells and the lower band of polymorphonuclear cells were removed to a clean 50-ml conical tube. An equal volume of 0.5 N Hanks' buffer was added to the cells in the 50-ml tube. Normal Hanks' buffer was added to bring the total volume to 50 ml. Tubes were spun at 400 g for 10 min at 4°C. The supernatant was discarded, and the cell pellet was resuspended with 3 ml of 0.2% NaCl and incubated for 3 min at room temperature. Three milliliters of cold 1.6% NaCl was added, and the solution was transferred to a 15-ml conical tube. Ice-cold normal Hanks' buffer was added to bring the total volume to 15 ml. Cells were centrifuged at 175 g for 10 min at 4°C. The supernatant was removed, and cells were resuspended in 5 ml of ice-cold Hanks' buffer. An aliquot was taken for cell count with a hemacytometer. Cells were centrifuged at 175 g for 10 min, and the supernatant was discarded. Neutrophils were resuspended in MEM + 10% FBS at 1 x 106 cells/ml.
Pretreatment of neutrophils. Freshly isolated neutrophils were incubated with 10 µM CV3988 (Sigma), a PAF receptor antagonist, for 10 min before their use in the neutrophil adherence assay.
Neutrophil adherence assay. HCAEC were grown to confluence on a 12-well plate. Cells were washed twice with MEM + 10% FBS. Stimulant in 500 µl of Hanks' buffer was added to HCAEC, and cells were stimulated for 10 min at 37°C. Five hundred microliters of neutrophils in suspension (5 x 105 cells) in MEM + 10% FBS was added to each of the wells and incubated for 10 min at room temperature. Medium and unbound neutrophils were removed and discarded. Plates were washed twice with prewarmed Dulbecco's PBS. One milliliter of 0.2% Triton X-100 was added to each well to lyse adherent neutrophils and HCAEC. Cell lysates were scraped from the plate and transferred to an Eppendorf tube. A 500-µl aliquot of neutrophil suspension was added to 500 µl of 0.2% Triton X-100 and used as the theoretical maximal binding sample. Five hundred microliters of distilled H2O and 500 µl of 0.2% Triton X-100 was used as the reference blank. Samples, theoretical maximal binding sample, and blank were sonicated (550 Sonic Dismembrator, Fisher Scientific, Pittsburgh, PA) for 10 s. To measure neutrophil peroxidase activity, 400 µl of cell lysate was transferred to a glass tube and 1 ml of PBS, 1.2 ml of Hanks buffer + BSA, 200 µl of 3,3'-dimethoxybenzidine, and 200 µl of 0.05% H2O2 were added. The cell lysate reaction mixture was incubated for 15 min at room temperature. Two hundred microliters of 1% sodium azide (NaN3) was added to stop the reaction. The absorbance was then measured with a 4050 UV/visible spectrophotometer (Biochrom, Cambridge, UK) at 460 nm.
Synthesis of lysoPlsCho. LysoPlsCho was prepared by alkaline hydrolysis of bovine heart choline glycerophospholipids as described previously (17). LysoPlsCho was isolated by column chromatography on a 2.5 x 60-cm column of silica with a stepwise gradient elution procedure (2). Palmitoyl lysoPlsCho was isolated by reverse-phase HPLC as described previously (5). Fast atom bombardment mass spectrometry (FAB-MS) analysis of the final product revealed <2 mol% alkyl ether choline lysophospholipid species.
Statistical analysis. Data were analyzed with Student's t-test. P values of <0.05 were considered statistically significant; P values of <0.01 were considered highly statistically significant.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
60% of lysoPlsCho was released from the apical surface and
40% remained cell associated (Fig. 1). Additionally,
60% of lysoPtdCho remained cell associated, with only 40% being released from the apical surface of the HCAEC monolayer. No increase in choline lysophospholipid release from the basolateral surface was observed, suggesting that lysoPlsCho and lysoPtdCho are released exclusively into the circulation and not directly into the subendothelial space. These data suggest that in order to play an arrhythmogenic role in the myocardium, choline lysophospholipids must cross the endothelium after being released from the apical surface. Previous data from our laboratory and others have demonstrated that choline lysophospholipids increase the permeability of the endothelial cell monolayer, possibly facilitating its passage to the underlying interstitium. The mechanisms whereby lysoPtdCho impairs endothelial cell barrier function have been found to be associated with activation of RhoA and formation of actin stress fibers, suggesting contraction of adjacent endothelial cells (3, 6, 7, 14). The first study to examine the effects of lysoPtdCho on HCAEC permeability demonstrated that this amphiphilic compound at concentrations between 7.5 and 30 µM increased the permeability of HCAEC grown on Transwell inserts (20). The authors of that study proposed that the increase in HCAEC may be a result of downregulation of tight junction proteins by lysoPtdCho. Release of choline lysophospholipids from HCAEC, passage of these metabolites across the endothelial cell monolayer, and their ability to cause alterations in the electrophysiological properties of cardiac myocytes provide a possible link between thrombin generation at sites of vascular injury and cardiac myocyte dysfunction as a result of increased HCAEC choline lysophospholipid generation and release. Additionally, the production of choline lysophospholipids by thrombin-stimulated HCAEC is dependent on the presence of thrombin on the apical surface of the monolayer. No significant release was observed when thrombin was present at the basolateral surface of the HCAEC monolayer. The concentration and time of thrombin incubation used in these experiments did not alter the electrical resistance measured across the HCAEC monolayer or cause visible cell retraction, suggesting that the HCAEC monolayer was intact. When the thrombin concentration was increased to 1 IU/ml, gaps appeared in the HCAEC monolayer and choline lysophospholipid release from the HCAEC apical surface was observed (data not shown). We hypothesize that HCAEC thrombin receptors demonstrate "sidedness," with all or a majority of the receptors present on the HCAEC apical surface. We are currently conducting electron microscopic studies to explore this possibility.
LysoPtdCho has been implicated in several studies as proinflammatory and atherogenic. In the vascular endothelium, lysoPtdCho increases the cell surface expression of several adhesion molecules and increases neutrophil adherence (8, 13, 21). In a previous study, we demonstrated (12) that thrombin stimulation of HCAEC results in activation of an iPLA2 that is selective for arachidonylated plasmalogen phospholipids. As shown in Fig. 1, the release of lysoPlsCho is over twofold that of lysoPtdCho after thrombin stimulation. Similar to the changes observed with lysoPtdCho, stimulation with lysoPlsCho results in increases in HCAEC surface expression of P-selectin, E-selectin, VCAM-1, and ICAM-1 (Fig. 6). Although the increases in cell surface expression of adhesion molecules may result in increased neutrophil adherence, our data suggest that the interaction between PAF expression on the endothelial cell surface and the PAF receptor on neutrophils is necessary (Fig. 7). Pretreatment of neutrophils with a PAF receptor antagonist significantly reduced the percentage of adherent neutrophils, demonstrating the importance of the PAF-PAF receptor interaction in the adherence of these cells.
These results demonstrate that the presence of thrombin at sites of vascular injury in the coronary circulation, resulting in increased lysoPtdCho and lysoPlsCho release from the apical surface, has the potential not only to initiate arrhythmias but to induce changes within the endothelium leading to increased neutrophil adherence and vascular inflammation.
| GRANTS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Bergelson LD. Lipid Biochemical Preparations. New York: Elsevier/North-Holland Biomedical, 1980, p. 141–143.
3. Birukova AA, Smurova K, Birukov K, Garcia JG, Verin AD. Role of Rho GTPases in thrombin-induced lung vascular endothelial cell barrier dysfunction. Microvasc Res 67: 64–77, 2004.[CrossRef][Web of Science][Medline]
4. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911–917, 1959.[Medline]
5. Creer MH, Gross RW. Reversed-phase high-performance liquid chromatographic separation of molecular species of alkyl ether, vinyl ether, and monoacyl lysophospholipids. J Chromatogr 338: 61–69, 1985.[Web of Science][Medline]
6. Huang F, Subbaiah PV, Holian O, Zhang J, Johnson A, Gertzberg N, Lum H. Lysophosphatidylcholine increases endothelial permeability: role of PKC-
and RhoA cross talk. Am J Physiol Lung Cell Mol Physiol 289: L176–L185, 2005.
7. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273: 245–248, 1996.[Abstract]
8. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90: 1138–1144, 1992.[Web of Science][Medline]
9. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115: 2715–2721, 2007.
10. Liu SJ, Creer MH, Kennedy RH, McHowat J. Alterations in Ca2+ cycling by lysoplasmenylcholine in adult rabbit ventricular myocytes. Am J Physiol Cell Physiol 284: C826–C838, 2003.
11. McHowat J, Creer MH. Lysophosphatidylcholine accumulation in cardiomyocytes requires thrombin activation of Ca2+-independent PLA2. Am J Physiol Heart Circ Physiol 272: H1972–H1980, 1997.
12. Meyer MC, Kell PJ, Creer MH, McHowat J. Calcium-independent phospholipase A2 is regulated by a novel protein kinase C in human coronary artery endothelial cells. Am J Physiol Cell Physiol 288: C475–C482, 2005.
13. Murohara T, Scalia R, Lefer AM. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ Res 78: 780–789, 1996.
14. Patterson CE, Lum H. Update on pulmonary edema: the role and regulation of endothelial barrier function. Endothelium 8: 75–105, 2001.[Web of Science][Medline]
15. Sedlis SP, Sequeira JM, Altszuler HM. Coronary sinus lysophosphatidylcholine accumulation during rapid atrial pacing. Am J Cardiol 66: 695–698, 1990.[CrossRef][Web of Science][Medline]
16. Snyder DW, Crafford WA Jr, Glashow JL, Rankin D, Sobel BE, Corr PB. Lysophosphoglycerides in ischemic myocardium effluents and potentiation of their arrhythmogenic effects. Am J Physiol Heart Circ Physiol 241: H700–H707, 1981.
17. Wheeldon LW, Schumert Z, Turner DA. Lipid composition of heart muscle homogenate. J Lipid Res 6: 481–489, 1965.[Abstract]
18. White MC, McHowat J. Protease activation of calcium-independent phospholipase A2 leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res 120: 597–605, 2006.[Web of Science][Medline]
19. Williams SD, Ford DA. Activation of myocardial cAMP-dependent protein kinase by lysoplasmenylcholine. FEBS Lett 420: 33–38, 1997.[CrossRef][Web of Science][Medline]
20. Yan S, Chai H, Wang H, Yang H, Nan B, Ya Q, Chen C. Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells. Surgery 138: 464–473, 2005.[CrossRef][Web of Science][Medline]
21. Zhu Y, Lin JH, Liao HL, Verna L, Stemerman MB. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta 1345: 93–98, 1997.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |